About the Company
we are an innovative clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical need. our pipeline is built on the broad therapeutic potential of our lead product candidate, karxt, an oral modulator of muscarinic receptors that are located both in the central nervous system, or cns, and various peripheral tissues. karxt is our proprietary product candidate that combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the cns. we have assembled a team with extensive expertise in the research, development and commercialization of numerous cns agents, as well as deep familiarity with the biology of neuropsychiatric disorders, such as schizophrenia and ad, including the role of muscarinic receptors in their potential treatment. we will leverage this expertise to develop a pip
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $KRTX News
Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio
Bristol Myers Squibb (NYSE: BMY) today announced that it has successfully completed its acquisition of Karuna Therapeutics, ...
Bristol Myers Squibb closes $14B Karuna deal
Bristol Myers Squibb said it completed its previously announced acquisition of Karuna Therapeutics Inc. – a Boston-based ...
Loss-Making Karuna Therapeutics, Inc. (NASDAQ:KRTX) Expected To Breakeven In The Medium-Term
Snowflake stock has dived in recent weeks, but Guggenheim says the cloud computing company can bounce back from its recent ...
30 Biggest Biotechnology Companies in the World
In this article, we will be taking a look at the 30 biggest biotechnology companies in the world. If you do not want to learn ...
Analysts Conflicted on These Healthcare Names: MDxHealth (MDXH), OrthoPediatrics (KIDS) and Karuna Therapeutics (KRTX)
Zimmerman covers the Healthcare sector, focusing on stocks such as GE Healthcare Technologies Inc, Tactile Systems Technology ... and MoonLake Immunotherapeutics. Karuna Therapeutics has an analyst ...
Bristol Myers wins FDA AdCom backing for Abecma label expansion
A group of FDA advisors voted on Friday to expand the labeling for Abecma, a multiple myeloma therapy from Bristol Myers (BMY ...
100 Stocks You Should Have Invested In 5 Years Ago
If you know even a little bit about finance and investing, then you probably know that the stock market offers the most ...
BMY Mar 2024 52.000 put
PRINCETON, N.J., March 18, 2024--Bristol Myers Squibb (NYSE: BMY) today announced that it has successfully completed its acquisition of Karuna Therapeutics, Inc. ("Karuna"). With the acquisition's ...
Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics
Bristol Myers Squibb (BMS) has successfully completed its acquisition of Karuna Therapeutics, Inc. Through this transaction, ...
Bristol Myers Squibb Completes Acquisition Of Karuna Therapeutics - Quick Facts
Bristol Myers Squibb (BMY) has successfully completed its acquisition of Karuna Therapeutics, Inc. Karuna shares have ceased trading ...
Loading the latest forecasts...